A Decade of Research. One Standard.

Long before peptide research entered the mainstream conversation, we were already deep into the science of human optimization. Nearly a decade ago, our founding team was researching nootropic compounds — racetams, cholinergics, and neuroprotective stacks — studying their mechanisms of action on cognitive performance and neural plasticity. This was years before biohacking became a buzzword.

That same curiosity drove us into body composition research. Over the years, we documented multiple complete transformations — recomposition cycles, lean mass protocols, and recovery-focused regimens — always grounded in published data and measurable outcomes. We did not follow trends. We followed the literature.

When peptide research compounds started showing real promise in peer-reviewed trials, it was a natural progression. We had the scientific literacy, the practical experience, and the obsessive attention to detail that this space demands.

When we started sourcing research peptides in the UAE, the experience was dismal. Compounds from local and regional suppliers consistently showed signs of degradation, sub-potent formulations, and poor sterility — even when accompanied by documentation that claimed otherwise.

Injection-site reactions were common. Potency did not match what was on the label. The certificates of analysis that did exist often could not be independently verified. We tested, compared, and documented everything — and the pattern was clear: the regional supply chain had a quality control problem that nobody was addressing.

For anyone conducting serious research, this is not a minor inconvenience. Unreliable starting materials compromise every downstream result. We decided that if we were going to continue working with these compounds, we needed to control the supply chain ourselves.

We did not want to be another reseller repackaging product from an anonymous source. So we went to the source.

If there is one thing that defines how we operate, it is an obsessive attention to detail. We are the kind of team that will spend weeks refining a logo by fractions of a millimetre, adjust print thickness until it is exactly right, and re-run an analytical report if a single data point looks off. That same obsessive standard applies to everything — from compound sourcing to packaging to the documentation that ships with every order.

Our team conducted an extensive due diligence process that took us across the globe, evaluating multiple GMP-certified manufacturing facilities in major peptide production hubs. We assessed raw material sourcing, synthesis methodology, quality management systems, sterility protocols, and analytical testing infrastructure firsthand — not through brochures or sales calls, but through on-site facility audits.

After evaluating numerous candidates, we established a direct manufacturing partnership with a facility that met our standards: current GMP certification, validated HPLC and LC-MS analytical pipelines, documented endotoxin and sterility controls, and a willingness to submit every batch to independent third-party verification through Janoshik Analytical.

That partnership is the foundation of everything we ship today.

• Research integrity — every batch is independently tested by Janoshik Analytical with HPLC verification. The COA ships with your order and is published in our public COA library.
• Radical transparency — our editorial policy, research standards, purity data, and pricing are all public. If we can not verify a claim, we do not make it.
• Direct manufacturing relationships — we work directly with our GMP-certified production partner. No middlemen, no anonymous brokers, no repackaged product.
• Cold-chain or nothing — peptides degrade in heat. Every shipment is temperature-controlled from storage through delivery, maintained at 2–8°C across the entire chain.
• Research use only — we operate strictly within UAE regulatory guidelines. Our compounds are supplied for in-vitro laboratory research. We do not make therapeutic claims, and we never will.

We are a small, focused team based in Dubai with backgrounds spanning neuroscience research, pharmaceutical sciences, body composition analysis, and supply chain operations. We believe a small team that cares deeply about quality will always outperform a large team that does not.

We are not trying to become the biggest peptide supplier. We are trying to become the most trusted one.

Our roadmap is straightforward: expand the compound library with the same verification standards that built our reputation, deepen our research content with more peer-cited articles, extend same-day delivery across the GCC, and build a community of researchers who hold us accountable.

We have been in this space for nearly a decade. We are not going anywhere — and every decision we make passes through one filter: does this make our researchers more confident in what they are working with?